Can less chemo keep bladder cancer in check? new trial investigates
NCT ID NCT07183319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether people with advanced bladder cancer can switch to a milder treatment after an initial strong combination therapy. Participants first receive two drugs (pembrolizumab and enfortumab vedotin) for 24 weeks. If their cancer is controlled, they then receive only pembrolizumab. The goal is to see if this de-escalation keeps the cancer from growing while reducing side effects. About 30 adults with metastatic urothelial carcinoma are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab and Enfortumab Vedotin
- What this could lead to
- If successful, this could show that some patients with metastatic bladder cancer can safely reduce their treatment intensity without losing disease control.
- What could go wrong
- This is a small, early-phase trial with only 30 participants. The cancer may progress during the de-escalation phase, and side effects from the drugs remain possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers